$15.10
1.48% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US74587B1017
Symbol
PLSE

Pulse Biosciences, Inc. Stock price

$15.10
-0.97 6.04% 1M
-6.34 29.57% 6M
-2.31 13.27% YTD
-0.55 3.51% 1Y
+13.21 698.94% 3Y
+4.63 44.22% 5Y
+10.93 262.11% 10Y
+10.93 262.11% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.22 1.48%

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$881.8m
Net debt
positive
Cash
$119.3m
Shares outstanding
67.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 785.1
EV/Sales
- | 691.6
EV/FCF
negative
P/B
8.5
Financial Health
Equity Ratio
86.7%
Return on Equity
-46.7%
ROCE
-50.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $1.3m
EBITDA
$-62.5m | -
EBIT
$-63.7m | $-79.7m
Net Income
$-60.2m | $-74.1m
Free Cash Flow
$-40.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-44.0% | -
EBIT
-42.7% | -46.7%
Net Income
-41.6% | -38.3%
Free Cash Flow
-10.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -5,812.1%
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-0.6
Short interest
15.8%
Employees
75
Rev per Employee
$0.0
Show more

Is Pulse Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Pulse Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pulse Biosciences, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pulse Biosciences, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Pulse Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
70% 70%
-
- Research and Development Expense 36 36
25% 25%
-
-63 -63
44% 44%
-
- Depreciation and Amortization 1.16 1.16
3% 3%
-
EBIT (Operating Income) EBIT -64 -64
43% 43%
-
Net Profit -60 -60
42% 42%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pulse Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pulse Biosciences, Inc. Stock News

Neutral
Business Wire
about 5 hours ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous El...
Neutral
Business Wire
12 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston. Pulse Biosciences' Management is scheduled to present on Wednesday, August 13, 2025, at 11:00 a...
Neutral
Business Wire
14 days ago
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a corresponding conference c...
More Pulse Biosciences, Inc. News

Company Profile

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.

Head office United States
CEO Paul LaViolette
Employees 75
Founded 2014
Website www.pulsebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today